Coherus Bio (CHRS)

Mar 25, 2025, 4:30 PM EDT - 9 days ago

Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 10, 2025, 8:52 PM EDT - 23 days ago

Coherus BioSciences, Inc. (CHRS) Q4 2024 Earnings Call Transcript

Mar 10, 2025, 4:12 PM EDT - 24 days ago

Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update

Mar 3, 2025, 8:30 AM EST - 4 weeks ago

Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025

Feb 24, 2025, 9:08 AM EST - 5 weeks ago

Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference

Dec 18, 2024, 8:30 AM EST - 3 months ago

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

Dec 16, 2024, 6:08 PM EST - 3 months ago

Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development

Dec 3, 2024, 9:34 AM EST - 4 months ago

Why Is Coherus BioSciences Stock Trading Higher On Tuesday?

Nov 27, 2024, 4:01 PM EST - 4 months ago

Coherus Management to Participate in the 2024 Citi Global Healthcare Conference

Nov 6, 2024, 11:09 PM EST - 5 months ago

Coherus BioSciences, Inc. (CHRS) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:01 PM EST - 5 months ago

Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 30, 2024, 4:20 PM EDT - 5 months ago

Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

Aug 13, 2024, 10:01 AM EDT - 8 months ago

Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects

Aug 9, 2024, 6:08 PM EDT - 8 months ago

Coherus BioSciences, Inc. (CHRS) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 9:00 AM EDT - 8 months ago

Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024

Jun 27, 2024, 8:26 AM EDT - 10 months ago

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

May 31, 2024, 12:04 PM EDT - 10 months ago

Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway

May 30, 2024, 9:00 AM EDT - 11 months ago

Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference

May 23, 2024, 5:51 PM EDT - 11 months ago

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 23, 2024, 9:00 AM EDT - 11 months ago

Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA

May 10, 2024, 12:07 AM EDT - 11 months ago

Coherus BioSciences, Inc. (CHRS) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:01 PM EDT - 11 months ago

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 7:30 AM EDT - 11 months ago

Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan

May 8, 2024, 9:00 AM EDT - 11 months ago

Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer

May 1, 2024, 4:30 PM EDT - 1 year ago

Coherus to Report First Quarter 2024 Financial Results on May 9, 2024

Apr 24, 2024, 10:02 AM EDT - 1 year ago

Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 8, 2024, 8:30 AM EDT - 1 year ago

Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting

Mar 20, 2024, 8:14 PM EDT - 1 year ago

Coherus Biosciences: Dumping One Drug But Showing Promise With Another

Mar 13, 2024, 8:56 PM EDT - 1 year ago

Coherus BioSciences, Inc. (CHRS) Q4 2023 Earnings Call Transcript

Mar 13, 2024, 4:01 PM EDT - 1 year ago

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update

Mar 5, 2024, 4:01 PM EST - 1 year ago

Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024

Mar 4, 2024, 1:00 AM EST - 1 year ago

Coherus Completes Divestiture of Ophthalmology Franchise

Feb 23, 2024, 5:33 PM EST - 1 year ago

Coherus BioSciences Announces New Employment Inducement Grants

Feb 21, 2024, 8:30 AM EST - 1 year ago

Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Feb 5, 2024, 8:00 AM EST - 1 year ago

Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP

Jan 22, 2024, 1:15 AM EST - 1 year ago

Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal

Jan 18, 2024, 4:05 PM EST - 1 year ago

Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium

Jan 4, 2024, 8:00 AM EST - 1 year ago

INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)

INO

Jan 3, 2024, 9:00 AM EST - 1 year ago

Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 2, 2024, 8:29 AM EST - 1 year ago

Coherus Announces U.S. Launch of LOQTORZI™

Dec 27, 2023, 6:56 AM EST - 1 year ago

2024 could turn into a ‘trader's market.' Here's how this strategist says you can make the most of that.

AAPL AMC BABA GME HUYA MARA MULN

Dec 26, 2023, 4:01 PM EST - 1 year ago

Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Dec 11, 2023, 8:30 AM EST - 1 year ago

Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx

Dec 7, 2023, 5:55 PM EST - 1 year ago

Coherus BioSciences Announces CFO Transition Plans

Dec 6, 2023, 4:00 AM EST - 1 year ago

Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress

Nov 15, 2023, 4:58 AM EST - 1 year ago

Coherus BioSciences Is A Buy On The Dip After Toripalimib Approval

Nov 7, 2023, 5:37 PM EST - 1 year ago

Coherus: The Surface Acquisition Is A Distraction

Nov 7, 2023, 12:03 AM EST - 1 year ago

Coherus BioSciences, Inc. (CHRS) Q3 2023 Earnings Call Transcript

Nov 6, 2023, 4:07 PM EST - 1 year ago

Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights

Nov 3, 2023, 8:30 AM EDT - 1 year ago

Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)